Whole tumor vs. FDG-directed dose escalation in patients with locally advanced NSCLC: evaluation of isotoxic treatment plans from the randomized ARTFORCE PET-Boost Trial
Cooke, S. de Ruysscher, D. Reymen, B. Lambrecht, M. Persson, G. F. Dieleman, E. M. van Diessen, J. Damen, E. Sikorska, K.
Cooke, S.
de Ruysscher, D.
Reymen, B.
Lambrecht, M.
Persson, G. F.
Dieleman, E. M.
van Diessen, J.
Damen, E.
Sikorska, K.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Cooke S, de Ruysscher D, Reymen B, Lambrecht M, Persson GF, Faivre-Finn C, et al. Whole Tumor vs. FDG-Directed Dose Escalation in Patients with Locally Advanced NSCLC: Evaluation of Isotoxic Treatment Plans from the Randomized ARTFORCE PETBoost Trial. International Journal of Radiation Oncology Biology Physics. 2022 Nov;114(3):E369-E70. PubMed PMID: WOS:000892639301155.